9.48
+0.28(+3.04%)
Currency In USD
Address
Building 5
Weybridge, KT13 0NY
United Kingdom of Great Britain and Northern Ireland
Phone
44 1932 822000
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
24561
First IPO Date
July 25, 2022
| Name | Title | Pay | Year Born |
| Mr. Brian James McNamara | Chief Executive Officer & Executive Director | 4.04M | 1966 |
| Ms. Dawn Amanda Allen | Chief Financial Officer & Director | 1.3M | 1968 |
| Ms. Lisa Paley | President of North America | 0 | 1967 |
| Ms. Claire Dickson | Chief Digital & Technology Officer | 0 | N/A |
| Ms. Tamara Rogers | Chief Marketing Officer | 0 | 1970 |
| Mr. Keith Choy | President of Asia Pacific | 0 | 1969 |
| Ms. Line De Decker | Chief Human Resources Officer | 0 | 1974 |
| Mr. Franck Riot | Chief R&D Officer | 0 | 1968 |
| Mr. Adrian Charles Morris | General Counsel | 0 | 1967 |
| Mr. Filippo Lanzi | President of EMEA & LatAm | 0 | N/A |
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.